You are here

Article Text

Article menu
Download PDFPDF
Letter
Interferon alpha eye drops: treatment of atypical lymphoid hyperplasia with secondary alopecia
  1. P T Finger,
  2. D Reichstein
  1. From The New York Eye Cancer Centre, The New York Eye and Ear Infirmary, New York City, New York, USA
  1. Correspondence to: Paul T Finger MD, The New York Eye Cancer Centre, 115 East 61st Street, New York City, New York, USA 10021; pfinger{at}eyecancer.com

https://doi.org/10.1136/bjo.2006.106930

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A typical lymphoid hyperplasia (ALH) of the conjunctiva is a benign tumour that can induce periorbital oedema and rarely corneal decompensation. Orbital ALH can cause optic nerve compression. While most ALH is localized and treatable by observation; some require local resection, immunosuppression and radiation therapy.1,2 When “observation as treatment” is elected, ALH should be periodically inspected for evidence of malignant transformation.3

    Topical chemotherapy has become an increasingly popular alternative in treatment of conjunctival tumours.4 Specifically, interferon-alpha eye drops have been used to treat squamous conjunctival malignancy with limited side effects.5–7 However, with systemic and subcutaneous administration, hair loss has been reported.8,9,10

    While ocular side effects such as follicular conjunctivitis and conjunctival hyperaemia have been …

    View Full Text

    Footnotes

    • Supported by The EyeCare Foundation, Inc., New York City, New York, USA. http://eyecarefoundation.org

    • Competing interests: The authors have no proprietary interest in any drugs used in this study.

      Informed consent was obtained for publication of the person’s details in this report.